Locke Warwick J, Zotenko Elena, Stirzaker Clare, Robinson Mark D, Hinshelwood Rebecca A, Stone Andrew, Reddel Roger R, Huschtscha Lily I, Clark Susan J
Epigenetic Research Laboratory, Genomics and Epigenetic Division, The Garvan Institute of Medical Research, 384 Victoria Street, Darlinghurst, NSW 2010 Australia ; St. Vincent's Clinical School, Faculty of Medicine, University of New South Wales, Level 5 deLacy Building, St Vincent's Hospital, Victoria Street, Darlinghurst, NSW 2010 Australia.
Swiss Institute of Bioinformatics, University of Zurich, Zurich, and Institute of Molecular Life Sciences, University of Zurich, Winterthurerstrasse 190, Zurich, CH-8057 Switzerland.
Clin Epigenetics. 2015 May 1;7(1):52. doi: 10.1186/s13148-015-0086-0. eCollection 2015.
Dysregulation of the epigenome is a common event in malignancy; however, deciphering the earliest cancer-associated epigenetic events remains a challenge. Cancer epigenome studies to date have primarily utilised cancer cell lines or clinical samples, where it is difficult to identify the initial epigenetic lesions from those that occur over time. Here, we analysed the epigenome of human mammary epithelial cells (HMEC) and a matched variant cell population (vHMEC) that have spontaneously escaped senescence and undergone partial carcinogenic transformation. Using this model of basal-like breast carcinogenesis, we provide striking new insights into the very first epigenetic changes that occur during the initial stages of malignancy.
The first phase of malignancy is defined by coordinated changes in the epigenome. At the chromatin level, this is embodied in long-range epigenetic deregulation, which involves the concomitant but atypical acquisition or loss of active and repressive histone modifications across large regional blocks. Changes in DNA methylation also occurs in a highly coordinated manner. We identified differentially methylated regions (DMRs) in the very earliest passages of vHMECs. Notably, we find that differential methylation targets loci regulated by key transcription factors including p53, AHR and E2F family members suggesting that epigenetic deregulation of transcription factor binding is a key event in breast carcinogenesis. Interestingly, DMRs identified in vHMEC are extensively methylated in breast cancer, with hypermethylation frequently encroaching into neighbouring regions. A subset of vHMEC DMRs exhibited a strong basal-like cancer specific hypermethylation.
Here, we generated epigenome-wide maps of the earliest phase of breast malignancy and show long-range epigenetic deregulation and coordinated DNA hypermethylation targets loci regulated by key transcription factors. These findings support a model where induction of breast cancer occurs through epigenetic disruption of transcription factor binding leading to deregulation of cancer-associated transcriptional networks. With their stability and very early occurrence, vHMECs hypermethylated loci could serve as excellent biomarkers for the initial detection of basal breast cancer.
表观基因组失调是恶性肿瘤中的常见现象;然而,解读最早与癌症相关的表观遗传事件仍然是一项挑战。迄今为止,癌症表观基因组研究主要利用癌细胞系或临床样本,在这些样本中很难从随时间发生的表观遗传损伤中识别出最初的损伤。在此,我们分析了人类乳腺上皮细胞(HMEC)和一个匹配的变异细胞群体(vHMEC)的表观基因组,该变异细胞群体已自发逃脱衰老并经历了部分致癌转化。利用这种基底样乳腺癌发生模型,我们对恶性肿瘤初始阶段发生的最初表观遗传变化提供了惊人的新见解。
恶性肿瘤的第一阶段由表观基因组的协调变化定义。在染色质水平上,这表现为远距离表观遗传失调,涉及在大的区域块中同时但非典型地获得或丧失活性和抑制性组蛋白修饰。DNA甲基化的变化也以高度协调的方式发生。我们在vHMEC的最早传代中鉴定出差异甲基化区域(DMR)。值得注意的是,我们发现差异甲基化靶向由关键转录因子包括p53、芳烃受体(AHR)和E2F家族成员调控的基因座,这表明转录因子结合的表观遗传失调是乳腺癌发生中的关键事件。有趣的是,在vHMEC中鉴定出的DMR在乳腺癌中广泛甲基化,高甲基化经常侵入邻近区域。一部分vHMEC DMR表现出强烈的基底样癌症特异性高甲基化。
在此,我们生成了乳腺癌恶性肿瘤最早阶段的全表观基因组图谱,并显示远距离表观遗传失调和协调的DNA高甲基化靶向由关键转录因子调控的基因座。这些发现支持一种模型,即乳腺癌的发生是通过转录因子结合的表观遗传破坏导致癌症相关转录网络失调。由于其稳定性和极早出现,vHMECs高甲基化位点可作为基底样乳腺癌初始检测的优秀生物标志物。